Compare · SLP vs VRSN
SLP vs VRSN
Side-by-side comparison of Simulations Plus Inc. (SLP) and VeriSign Inc. (VRSN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SLP and VRSN operate in EDP Services (Technology), so they compete in similar markets.
- VRSN is the larger of the two at $25.27B, about 68.5x SLP ($368.7M).
- VRSN has been more active in the news (7 items in the past 4 weeks vs 6 for SLP).
- SLP has more recent analyst coverage (10 ratings vs 7 for VRSN).
- Company
- Simulations Plus Inc.
- VeriSign Inc.
- Price
- -
- -
- Market cap
- $368.7M
- $25.27B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- EDP Services
- EDP Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1998
- News (4w)
- 6
- 7
- Recent ratings
- 10
- 7
Simulations Plus Inc.
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.
VeriSign Inc.
VeriSign, Inc., together with its subsidiaries, provides domain name registry services and internet infrastructure that enables internet navigation for various recognized domain names worldwide. It enables the security, stability, and resiliency of internet infrastructure and services, including providing root zone maintainer services, operating two of the 13 internet root servers; and offering registration services and authoritative resolution for the .com and .net domains, which support global e-commerce. VeriSign, Inc. was incorporated in 1995 and is headquartered in Reston, Virginia.
Latest SLP
- SEC Form 10-Q filed by Simulations Plus Inc.
- Simulations Plus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Simulations Plus Reports Third Quarter Fiscal 2026 Financial Results
- SEC Form PREM14A filed by Simulations Plus Inc.
- Chief Revenue Officer Dibella John Anthony Ii sold $18,360 worth of shares (1,000 units at $18.36) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 86,140 units (SEC Form 4)
- Director Woltosz Walter S sold $77,024 worth of shares (4,177 units at $18.44) as part of a pre-agreed trading plan, decreasing direct ownership by 0.13% to 3,202,131 units (SEC Form 4)
- Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit
- President, Services Solutions Fiedler-Kelly Jill exercised 7,350 shares at a strike of $10.05 and sold $133,770 worth of shares (7,350 units at $18.20) as part of a pre-agreed trading plan (SEC Form 4)
- Simulations Plus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
- President, Services Solutions Fiedler-Kelly Jill exercised 1,050 shares at a strike of $10.05 and sold $17,336 worth of shares (1,050 units at $16.51) as part of a pre-agreed trading plan (SEC Form 4)
Latest VRSN
- Wedbush resumed coverage on VeriSign with a new price target
- Exec. Chairman, Pres, & CEO Bidzos D James sold $883,875 worth of shares (3,300 units at $267.84), decreasing direct ownership by 0.78% to 419,539 units (SEC Form 4)
- EVP, Gen Counsel & Secretary Indelicarto Thomas C sold $67,308 worth of shares (250 units at $269.23), decreasing direct ownership by 0.69% to 36,051 units (SEC Form 4)
- Exec. Chairman, Pres, & CEO Bidzos D James sold $878,105 worth of shares (3,300 units at $266.09), decreasing direct ownership by 0.77% to 422,839 units (SEC Form 4)
- EVP, Gen Counsel & Secretary Indelicarto Thomas C sold $63,958 worth of shares (250 units at $255.83), decreasing direct ownership by 0.68% to 36,301 units (SEC Form 4)
- Exec. Chairman, Pres, & CEO Bidzos D James sold $828,110 worth of shares (3,300 units at $250.94), decreasing direct ownership by 0.77% to 426,139 units (SEC Form 4)
- Verisign to Report Second Quarter 2026 Financial Results
- VeriSign Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- VeriSign Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Exec. Chairman, Pres, & CEO Bidzos D James sold $820,141 worth of shares (3,300 units at $248.53), decreasing direct ownership by 0.76% to 429,439 units (SEC Form 4)